• Data support that targeting NRP1 with antisense oligonucleotides is a promising therapeutic strategy for solid cancers where current immunotherapies show limited benefit
• SECN-15 demonstrates meaningful anti-tumor activity as well as excellent safety and tolerability profile in vivo
• Gastric cancer selected as a lead indication for planned Phase I/II clinical trial

Martinsried (Munich), Germany, May 23, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, will present new data  on the company’s lead program, SECN-15, a potential first-in-class antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 4 in Chicago, Illinois, USA.

Martinsried (Munich), Germany, May 12, 2025 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced the signing of a research and option agreement for a scientific and strategic collaboration with one of Curie.Bio’s portfolio companies.

• Prof. Dr. Dario A.A. Vignali brings vast knowledge from groundbreaking cancer research work in immune regulation and the immunosuppressive tumor microenvironment
• His expertise in the field of immuno-oncology and in particular NRP1, the target of Secarna’s lead asset, SECN-15, will help translate the Company’s scientific discoveries into significant clinical strategies
• Prof. Vignali joins current SAB members Prof. Dr. Alexander M.M. Eggermont and Prof. Dr. Alfred Zippelius, both cancer research key opinion leaders